Inhibition of intrahepatic hepatitis B virus replication by antiviral drugs in a novel transgenic mouse model.

Abstract

Transgenic mice which carry the integrated human hepatitis B virus (HBV) genome and produce HBV particles in the liver were treated with antiviral compounds, and the amount of viral DNA in the liver and serum was monitored by Southern analyses. Mouse alpha interferon (200,000 U per injection, twice daily for 3 days) and a novel nucleoside, oxetanocin G (15 mg/kg of body weight per injection, twice daily for 7 days), inhibited viral DNA synthesis in the liver almost completely. This animal model should prove useful in evaluating anti-HBV agents.

• Authors: T Nagahata, K Araki, K Yamamura, K Matsubara
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 36 Issue 9 Pg. 2042-5 (Sep 1992) ISSN: 0066-4804 [Print] United States
• PMID: 1416898 (Publication Type: Journal Article)

Chemical References

• Antiviral Agents
• DNA, Viral
• Hepatitis B Surface Antigens
• Interferon-alpha
• oxetanocin G
• Guanine
• Vidarabine

Topics

• Animals
• Antiviral Agents (pharmacology)
• Blotting, Southern
• DNA, Viral (analysis)
• Guanine (analogs & derivatives, pharmacology)
• Hepatitis B Surface Antigens (analysis)
• Hepatitis B virus (drug effects)
• Interferon-alpha (pharmacology)
• Kidney (microbiology)
• Liver (drug effects, microbiology)
• Male
• Mice
• Mice, Transgenic
• Vidarabine (pharmacology)
• Virus Replication (drug effects)